Clinical trial
Cyclosporine in Treating Patients With Recurrent or Refractory…
NCT00070291 · Eastern Cooperative Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00070291 |
|---|---|
| Title | Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma |
| Official title | A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | cyclosporine |
| Enrollment | 4 |
| Start date | Jan 24, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | May 1, 2011 |
| First posted | Oct 7, 2003 |
| Last update posted | Jun 29, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: